迪瑞医疗(300396) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥662,535,125.59, representing a 99.60% increase compared to ¥331,932,094.69 in the same period last year[5] - Net profit attributable to shareholders was ¥121,800,597.55, up 56.73% from ¥77,711,739.74 year-on-year[5] - Basic earnings per share increased to ¥0.4466, reflecting a growth of 55.88% from ¥0.2865 in the same period last year[5] - Operating profit for Q1 2024 was ¥141,411,003.12, up 65.5% from ¥85,536,589.74 in Q1 2023[29] - The company reported a total comprehensive income of ¥122,335,562.33 for Q1 2024, up from ¥77,112,800.85 in Q1 2023, indicating a growth of 58.6%[29] - Other income for Q1 2024 was ¥14,239,074.57, which is an increase from ¥5,759,205.99 in the same period last year[28] Cash Flow and Assets - The net cash flow from operating activities decreased significantly to -¥184,049,664.39, a decline of 3,005.07% compared to -¥5,927,387.04 in the previous year[5] - Cash flow from operating activities showed a net outflow of ¥184,049,664.39, compared to a smaller outflow of ¥5,927,387.04 in the same period last year[31] - The net cash flow from investment activities was 16,503,423.86, compared to a negative cash flow of -13,914,595.87 in the previous year[32] - The total cash inflow from financing activities was 45,151,555.82, with cash outflows totaling 47,987,150.92, resulting in a net cash flow of -2,835,595.10[32] - The ending balance of cash and cash equivalents was 670,694,518.02, compared to 774,335,835.87 at the end of the previous year[32] - Current assets decreased to CNY 1,960,804,503.21 from CNY 2,043,754,535.72, indicating a decline of about 4.1%[24] - Cash and cash equivalents fell to CNY 674,589,116.02 from CNY 845,730,745.23, a decrease of approximately 20.2%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,501[15] - The largest shareholder, Shenzhen Huade Xinrun Equity Investment Enterprise, holds 28.15% of shares, totaling 77,288,400 shares, with 45,600,156 shares pledged[15] - Guangdong Hengjian International Investment Co., Ltd. holds 12.06% of shares, totaling 33,123,600 shares[15] - The total number of shares held by the top 10 shareholders amounts to significant ownership concentration, with the top three shareholders alone holding over 50%[15] - The company maintains a diverse shareholder base, including institutional investors such as China Construction Bank and Taikang Life Insurance[15] - There are no reported related party transactions among the top shareholders, except for familial relationships among some[16] Liabilities and Equity - The company’s total liabilities amounted to CNY 1,091,237,710.16, down from CNY 1,281,453,034.50, indicating a decrease of about 14.8%[25] - Total current liabilities decreased to CNY 1,040,965,426.50 from CNY 1,231,843,749.69, a reduction of approximately 15.5%[25] - The company’s equity capital remained stable at CNY 274,698,458.00, with a slight decrease in capital reserve from CNY 259,045,612.47 to CNY 256,980,029.91[25] Research and Development - Research and development expenses rose by 44.13% to ¥3,200,000, driven by increased salaries for R&D personnel and material costs for ongoing projects[12] - Research and development expenses for Q1 2024 were ¥32,040,993.06, an increase of 44% from ¥22,230,348.74 in Q1 2023[28] Future Plans - The company plans to enhance its product diversification and strengthen partnerships with large clients to drive future growth[9] - The company plans to repurchase and cancel 1,379,750 shares of restricted stock due to performance conditions not being met, which includes 152,250 shares from departed employees[22] Miscellaneous - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[16] - The report indicates that there are no preferred shareholders or changes in restricted shares during the period[17] - The company has a total of 4,305,776 shares released from lock-up for Song Jie, reflecting a significant reduction in restricted shares[18] - The company has not yet audited the first quarter report[33] - The company has adopted new accounting standards starting from 2024[33]